PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

57 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-05-31

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is:

To validate the efficacy of multiparametric MRI, FDG-PET, RGD-PET, and PET-MR fusion imaging in the prediction and monitoring response to neoadjuvant chemotherapy of locally advanced breast cancer patients.

To identify the optimal combination parameters of MR spectroscopy, diffusion-weighted MRI, dynamic contrast-enhanced MRI, FDG-PET, and RGD-PET in the prediction and monitoring response to neoadjuvant chemotherapy of locally advanced breast cancer patients.

To compare the performances of dynamic contrast-enhanced MRI using parametric response map analysis versus those of pharmacokinetic parameters (Ktrans, kep, or Ve) in the early prediction of pathological responsiveness to neoadjuvant chemotherapy in breast cancer patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FDG PET-CT in Advanced Breast Cancer

NCT07173868

Histologically Confirmed Metastatic or Locally Advanced Breast Cancer With no Radical Topical Treatment Available If There is Liver Metastasis, Which the Researcher Believes Will be Difficult to Evaluate the Response Accurately With Bone Metastasis or CT

RECRUITING

PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer

NCT00236275

Breast Cancer

COMPLETED PHASE3

Integrated Positron Emission Tomography Magnetic Resonance (PET/MR) of Breast Cancer

NCT02766530

Breast Cancer

UNKNOWN PHASE4

PET/MR in Surgical Planning for Breast CA Treated With Neoadj Chemo

NCT04149353

Breast Cancer

TERMINATED NA

Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer

NCT04411966

Metastatic Breast Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Enrolled women with breast cancers who had received an anthracycline-taxane regimen and subsequent surgery were prospectively enrolled. DCE-MRI and FDG-PET scan were performed before and after the 1st cycle of chemotherapy. MR imaging parameters and SUV on PET scan within a tumor were analyzed. Clinicopathologic (age, clinical tumor stage, hormonal receptor status, and surgery type) and imaging parameters were compared according to the pathological response.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pathologically confirmed breast cancer
* Clinical stage IIb, IIIa, IIIb, IIIc
* Must have measurable disease
* Performance status of ECOG 0-2
* Adequate, bone marrow, liver, heart, and renal function
* Who did not receive chemotherapy for breast cancer
* Must agree with and signed informed consent

Exclusion Criteria

* Prior history of cancer besides breast cancer
* Active bacterial infection
* Pregnant or lactating women
* Psychological disease or seizure
* History of arrhythmia, congestive heart failure, myocardial infarct, or unstable angina
* Male breast cancer
* Who had a pacemaker or history of open heart surgery

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No